Korro Bio, Inc. (KRRO)
(Delayed Data from NSDQ)
$16.00 USD
+0.14 (0.88%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $16.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRRO 16.00 +0.14(0.88%)
Will KRRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KRRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRRO
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet
KRRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KRRO
Korro Bio (KRRO) Buy Rating Reiterated by HC Wainwright & Co. | KRRO Stock News
Korro Bio (KRRO) Secures EMA Orphan Drug Designation for KRRO-110 | KRRO Stock News
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 | KRRO Stock News
Korro Bio receives European Medicines Agency granted ODD for KRRO-110
Korro Bio management to meet with Piper Sandler